Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Enrico Pesenti et al.|Molecular Cancer Therapeutics|2010Cited by 63
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic LeukaemiaAlessia Casolaro, Rachele Alzani, Josée Golay et al.|PLoS ONE|2013Cited by 34
Abstract A179: NMS-P113, a novel orally available JAK2 selective inhibitorPaola Gnocchi, Arturo Galvani, Maria Gabriella Brasca et al.|Molecular Cancer Therapeutics|2015Cited by 0
Supplementary Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Rachele Alzani et al.|Unknown|2023Cited by 0
Data from Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor EfficacyClara Albanese, Marina Ciomei, Francesco Colotta et al.|Unknown|2023Cited by 0